MORRIS PLAINS, N.J., Dec. 14, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it was awarded US patent 8,076,140, "Mammalian cell lines for increasing longevity and protein yield from a cell culture."
